Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
2023 Preview
Biotech and pharma: from bad to worse, or better in 2023? Amy Brown and Edwin Elmhirst from Evaluate Vantage, discuss what the coming year is likely to bring.
A new year, a fresh outlook for beaten-up biotech companies? There are some hopes that conditions will improve during 2023, though few are expecting a dramatic recovery. View the webinar for expert views on the year ahead, and a look at the challenges and opportunities that will present themselves.
Get insights on:
- Which areas and indications look set to take off in 2023
- What's the impact of the macroeconomic landscape on the life sciences market?
- The big players and the new drugs set to drive growth
- The latest IPO and dealmaking activity
For the full data you can download the 2023 Preview report
Industry trends
Share This Article
To revisit the data or review some of the key themes discussed, please download the webinar slides
